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Gilles de la Tourette Syndrome (TS) is a childhood-onset neurodevelopmental disorder
that is characterized by multiple motor and phonic tics. It has a complex etiology
with multiple genes likely interacting with environmental factors to lead to the onset
of symptoms. The genetic basis of the disorder remains elusive. However, multiple
resources and large-scale projects are coming together, launching a new era in the field
and bringing us on the verge of discovery. The large-scale efforts outlined in this report are
complementary and represent a range of different approaches to the study of disorders
with complex inheritance. The Tourette Syndrome Association International Consortium
for Genetics (TSAICG) has focused on large families, parent-proband trios and cases
for large case-control designs such as genomewide association studies (GWAS),
copy number variation (CNV) scans, and exome/genome sequencing. TIC Genetics
targets rare, large effect size mutations in simplex trios, and multigenerational families.
The European Multicentre Tics in Children Study (EMTICS) seeks to elucidate gene-
environment interactions including the involvement of infection and immune mechanisms
in TS etiology. Finally, TS-EUROTRAIN, a Marie Curie Initial Training Network, aims to act
as a platform to unify large-scale projects in the field and to educate the next generation
of experts. Importantly, these complementary large-scale efforts are joining forces to
uncover the full range of genetic variation and environmental risk factors for TS, holding
great promise for identifying definitive TS susceptibility genes and shedding light into the
complex pathophysiology of this disorder.
Keywords: Gilles de la Tourette syndrome, genetics of complex disorders, neurodevelopmental disorders, GWAS
(genomewide association study), gene-environment interactions, next generation sequencing, collaborative
studies
INTRODUCTION
Gilles de la Tourette Syndrome (TS; OMIM #137580) is a childhood-onset neurodevelopmental
disorder, characterized by motor and vocal tics. Previous prevalence estimates ranged from 0.4
to 3.8% (Robertson, 2008); however, a recent meta-analysis refined the prevalence estimate to
0.3–0.9% (Scharf et al., 2015). TS often presents with co-morbidities such as attention deficit
hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD) (Swain et al., 2007),
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but autism spectrum disorders (ASD), depressive, and anxiety
disorders may be also present (Hirschtritt et al., 2015). This
overlap across disorders supports the hypothesis of a shared
neurological background and genetic susceptibility (Mathews
and Grados, 2011; Yu et al., 2015). Twin and family studies
have long established that TS bears a strong genetic component
(Pauls et al., 2014). However, TS is a complex disorder and
has been associated with several environmental factors as well,
with Group-A Streptococcal (GAS) infection and psychosocial
stress being the most prominent among them (Hoekstra et al.,
2013; Mathews et al., 2014). Despite the extensive research to
unravel the genetic basis of TS, the field is still in its nascence.
A simple PubMed search for “tic disorders” (26/3/2016) yields
5200 articles, far behind in comparison to those found for other
childhood-onset neurodevelopmental disorders, such as ADHD
(27,706 articles) and autism (33,167 articles), or related disorders
such as OCD (16,445 articles). However, as presented at the
First World Congress on Tourette Syndrome and Tic Disorders
(London, June 24–26, 2015), and as described further here,
the field of TS genetics stands at the precipice of discovery,
thanks to the concerted efforts of multiple researchers from
around the world and the coordination of multiple large-scale
collaborative projects funded by the European Commission and
the US National Institutes of Health.
The large-scale efforts outlined in this report, are
complementary and represent a range of different approaches
for the study of multifactorial disorders. The Tourette Syndrome
Association International Consortium for Genetics (TSAICG)
focuses on large families, sibpairs, trios, and cases for large case-
control designs such as genomewide association studies (GWAS),
copy number variation (CNV) scans, and exome/genome
sequencing. TIC Genetics studies simplex trios as well as
multigenerational families targeting rare, large effect size
mutations. The European Multicentre Tics in Children Study
(EMTICS) seeks to elucidate gene-environment interactions
including the involvement of infection and immune mechanisms
in TS etiology. Finally, TS-EUROTRAIN is a training network,
aiming to act as a platform to unify large-scale projects in the
field and educate the next generation of experts. To set the stage
for the description of the aims of these consortia we briefly
report the most notable findings that have shaped our current
knowledge for TS genetic susceptibility (excellent exhaustive
reviews are available in the literature) (State, 2011; Deng et al.,
2012; Paschou, 2013; Sun et al., 2016).
Candidate Gene Association Studies
Based on findings from pathophysiological studies, hypotheses
about the neuroanatomical regions affected in TS, and
therapeutic response to neuroleptics, the first TS candidate
genes were members of the dopaminergic, serotonergic, and
glutamatergic pathways (Peterson et al., 2003; Kalanithi et al.,
2005; Hartmann and Worbe, 2013; Table 1). Despite years of
effort, results have been inconsistent, possibly owing to the small
sample size of each individual study, the restricted number of
variants explored in each study, and the inherent difficulties of
candidate gene studies in genetically heterogenous disorders.
Chromosomal Aberration Studies
SLITRK1 has become the focus of debate in the TS literature
following the discovery of a de novo inversion in a TS
patient (Abelson et al., 2005). Although follow-up studies could
not find novel SLITRK1 mutations in a large number of
patients (Deng et al., 2006; Chou et al., 2007; Scharf et al.,
2008; Zimprich et al., 2008; Miranda et al., 2009), tagging-
SNP-based association studies supported the implication of
unidentified SLITRK1 regulatory variants (Miranda et al., 2009;
Karagiannidis et al., 2012). Tracing chromosomal aberrations in
TS patients, IMMP2L has also been implicated in TS (Boghosian-
Sell et al., 1996; Kroisel et al., 2001; Petek et al., 2001; Patel
et al., 2011; Katuwawela, 2012) and other neurodevelopmental
disorders, such as ASD, ADHD and dyslexia (Elia et al.,
2010; Maestrini et al., 2010; Pagnamenta et al., 2010; Girirajan
et al., 2011); yet IMMP2L coding mutations have not been
identified (Petek et al., 2007). Other cytogenetic abnormalities
associated with TS have implicated signal transduction and cell-
adhesion proteins, such as CNTNAP2 (Verkerk et al., 2003;
Poot et al., 2010) and NLGN4 (Lawson-Yuen et al., 2008;
Table 1).
CNV Studies
Scans of structural variations in relation to TS have revealed
de novo or recurrent rare CNVs in multiple genes (Table 1).
Of particular interest is the significant overlap of rare
CNVs observed in TS individuals with patients of other
neuropsychiatric and neurodevelopmental disorders, including
OCD, autism, ASD, and schizophrenia, suggesting shared
etiology (Sundaram et al., 2010; Fernandez et al., 2012; McGrath
et al., 2014).
Linkage Analysis Studies
Early linkage studies on large multigenerational pedigrees
failed to identify a major TS susceptibility gene (Deng et al.,
2012; Paschou, 2013), and the single-gene hypothesis was
soon abandoned. Recently, Ercan-Sencicek et al. identified an
extremely rare non-sense mutation in HDC, in a unique family
with several affected siblings, spurring again the interest for
monogenic TS and introducing the involvement of the, until
recently, ignored histaminergic pathway and its role in striatal
dopamine regulation (Ercan-Sencicek et al., 2010; Castellan
Baldan et al., 2014; Rapanelli et al., 2014). Although HDC
mutations have been extremely rare in the literature (Lei et al.,
2012), there is still evidence for association of the histaminergic
pathway genes and TS (Fernandez et al., 2012; Karagiannidis
et al., 2013).
GWAS Studies
The first TS GWAS was published in 2013, including 1285 cases
and 4964 ancestry-matched controls. While no marker achieved
a genomewide significance threshold, the strongest signal was
observed for an intronic single nucleotide polymorphism (SNP)
in COL27A1 (Scharf et al., 2013). Moreover, a replication
study of 42 top-signal SNPs from the first TS GWAS in
609 independent cases and 610 ancestry-matched controls,
revealed the most significant association to date with a
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TABLE 1 | List of genes that have so far been implicated in TS etiology.
Experimental approach by
which the gene was initially
identified
Gene Protein function Study sample size References
CANDIDATE GENE
Dopamine receptor D2 DRD2 Dopamine receptor 147 TS cases/314 controls Comings et al., 1991
225 TS cases/67 controls Comings et al., 1996
151 TS cases/183 controls Lee et al., 2005
69 trios Herzberg et al., 2010
Dopamine receptor D4 DRD4 Dopamine receptor 12 trios/3 large families Grice et al., 1996
61 OCD cases with and
without tics
Cruz et al., 1997
110 trios Díaz-Anzaldúa et al., 2004
Dopamine transporter [Solute
carrier family 6 (neurotransmitter
transporter), member 3]
DAT1 (SLC6A3) Dopamine transporter 225 TS cases/67 controls Comings et al., 1996
110 trios Díaz-Anzaldúa et al., 2004
103 trios Tarnok et al., 2007
266 TS cases/236 controls Yoon et al., 2007
Dopamine beta hydroxylase DBH Dopamine metabolism
(transformation of dopamine
to norepinephrine)
352 TS cases/148 controls Comings et al., 1996
Monoamine oxidase-A MAOA Dopamine and serotonin
metabolism (inactivation)
229 TS cases/90 relatives of
TS/57 controls
Gade et al., 1998
110 trios Díaz-Anzaldúa et al., 2004
Serotonin receptor 1A HTR1A Serotonin receptor 56 TS cases/20 controls Lam et al., 1996
Serotonin receptor 2C HTR2C Serotonin receptor 87 TS cases/311 controls Dehning et al., 2010
Serotonin transporter [Solute carrier
family 6 (neurotransmitter
transporter), member 4]
SERT (SLC6A4) Serotonin transporter 151 TS cases/858 controls Moya et al., 2013
5-HTTLPR locus – 151 TS cases/858 controls Moya et al., 2013
Tryptophan hydroxylase TPH2 Serotonin metabolism
(synthesis)
98 TS cases/178 controls Mössner et al., 2007
Glutamate transporter [Solute
carrier family 1 (glial high affinity
glutamate transporter), member 3]
EAAT1 (SLC1A3) Glutamate transporter 256 TS cases/224 controls Adamczyk et al., 2011
CHROMOSOMAL ABERRATIONS
Slit and Trk-like, Family Member 1 SLITRK1 Neurite outgrowth 175 TS cases/2148 controls Abelson et al., 2005
222 trios Karagiannidis et al., 2012
Inner mitochondrial membrane
protein 2L
IMMP2L Targets proteins to the inner
mitochondrial membrane
(exact role unknown)
De novo duplication in one
TS patient
Petek et al., 2001
De novo duplication in one
TS patient
Kroisel et al., 2001
De novo translocation in
one TS patient
Patel et al., 2011
Contactin associated protein-like 2 CNTNAP2 Cell-cell interaction
(myelinated axon-glia
junction) and membrane
potential (interaction with
voltage-activated potassium
channel)
One family Verkerk et al., 2003
460 TS cases/1131 controls Fernandez et al., 2012
(Continued)
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TABLE 1 | Continued
Experimental approach by
which the gene was initially
identified
Gene Protein function Study sample size References
Neuroligin 4 NLGN4 Post-synaptic cell adhesion
(synaptogenesis and
synapse remodeling)
One family Lawson-Yuen et al., 2008
COPY NUMBER VARIANTS
Neurexin 1 NRXN1 Pre-synaptic cell adhesion
(synapse formation)
111 TS cases/73 controls Sundaram et al., 2010
460 TS cases/1131 controls Fernandez et al., 2012
210 TS cases/285 controls Nag et al., 2013
Arylacetamide deacetylase AADAC Detoxification (drug
metabolism)—Unknown
function in the brain
111 TS cases/73 controls Sundaram et al., 2010;
Bertelsen et al., 2015243 TS cases/1571 controls
(initial study)
1181 TS cases/118730
controls (meta-analysis)
Catenin alpha 3 CTNNA3 Cytoskeleton modeling
(actin fillament assembly)
111 TS cases/73 controls Sundaram et al., 2010
460 TS cases/1131 controls Fernandez et al., 2012
Fibrous sheath CABYR binding
protein
FSCB Ca2+-binding protein
involved in fibrous sheath
biogenesis
111 TS cases/73 controls Sundaram et al., 2010
Voltage-gated potassium channel
(KCNE1, KCNE2) and regulator of
calcineurin 1 (RCAN1)
KCNE1-KCNE2-
RCAN1
locus
Neuronal cell membrane
repolarization (KCNE1,
KCNE2) and intracellular
calcineurin-mediated
signaling (RCAN1)
111 TS cases/73 controls Sundaram et al., 2010
Collagen, type VIII, alpha 1 COL8A1 Connective tissue and
basement membrane
component (extracellular
matrix collagen)
210 TS cases/285 controls Nag et al., 2013
LINKAGE STUDIES
Histidine decarboxylase HDC Histidine metabolism
(synthesis)
One large family Ercan-Sencicek et al., 2010
520 trios Karagiannidis et al., 2013
GENOMEWIDE ASSOCIATION STUDIES
Collagen, type XXVII, alpha 1 COL27A1* Connective tissue
component (extracellular
matrix collagen)
1285 TS cases/4964
controls (initial GWAS)
Scharf et al., 2013
1496 TS cases/5249
controls (meta-analysis)
Netrin 4 rs2060546 (proximal to
NTN4)
Extracellular protein that
directs axon outgrowth and
guidance
609 TS cases/610 controls
(initial analysis)
Paschou et al., 2014
1894 TS cases/5574
controls (meta-analysis)
As described in detail in the text, associations still remain inconclusive with difficulties in replicating original positive findings. To date, the heterogeneity of the disorder and small sample
sizes have been hampering the identification of TS susceptibility genes and, large scale studies like the ones described in this perspective, hold the promise to unravel the genetic basis
of TS.
*Only the top hit is shown here. No SNP reached genomewide significance levels.
SNP lying closest to NTN4, an axon guidance molecule
expressed in the developing striatum (Paschou et al., 2014).
The first ever epigenome-wide association study of tic disorders
revealed association signals nearby genes previously associated
with neurological disorders that warrant further investigation
(Zilhão et al., 2015).
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THE TOURETTE SYNDROME
ASSOCIATION INTERNATIONAL
CONSORTIUM FOR GENETICS
(TSAICG)—GENOMEWIDE ASSOCIATION
STUDIES FOR TS
The TSAICG was founded in 1986 by TS genetic researchers in
the United States and The Netherlands and brought together
by the TSA-USA to exchange ideas and share preliminary
data with the goal of identifying TS susceptibility genes. Early
studies focused on parametric linkage analyses in large, multi-
generational TS families (Pakstis et al., 1991; Barr et al., 1999)
under the assumption that TS was a monogenic disorder.
However, as evidence mounted to indicate the presence of non-
Mendelian inheritance (Kurlan et al., 1994; Hasstedt et al., 1995),
the TSAICG expanded to 11 clinical sites in USA, Canada,
Germany, the UK, and the Netherlands to collect TS affected
sibling pairs for non-parametric analyses using a standardized
phenotypic assessment for TS, OCD, and ADHD, still used today
by the three international TS consortia discussed here. The
TSAICG was awarded NIH funding in 2000 to collect additional
small nuclear families and completed a high-density linkage
study of all existing affected sibpairs and multi-generational
families (TSAICG, 2007). These analyses of over 2000 individuals
identified a genomewide significant non-parametric linkage
signal on chromosome 2p (TSAICG, 2007), though subsequent
analyses have demonstrated significant heterogeneity across this
locus, consistent with the presence of multiple distinct signals
within the linkage region (O’Rourke et al., 2009).With the advent
of the GWAS era, the TSAICG changed its collection goals to
focus on association studies using both parent-proband trios and
individual TS cases. These collections served as the basis for the
first TS GWAS and parallel CNV analysis as described above
(Scharf et al., 2013; McGrath et al., 2014). As it became clear
that sample size is the major hindrance to gene discovery for
complex neuropsychiatric traits, the TSAICG added additional
recruitment sites and novel recruitment and assessmentmethods,
such as web-based assessments of previously diagnosed TS cases
and remote DNA collection using commercial laboratories across
the US (Egan et al., 2012; Darrow et al., 2015). These online
protocols facilitated collection of 1600 independent TS cases
over the course of 2 years, a sample that served as the basis
for the second TS GWAS and CNV studies whose preliminary
results were presented at the First World Congress on Tourette
Syndrome and Tic Disorders (to be published by fall 2016).
Each of these large-scale TS genetic studies have relied
heavily on extended collaborations and data sharing, both within
the TSAICG as well as across additional US and European
research groups. The Gilles de la Tourette Syndrome GWAS
Replication Initiative (GGRI) consists of multiple TS research
groups across USA, Canada, France, Germany, Austria, Hungary,
Italy, Greece and Poland, and formed out of an NIH TS Genetics
Workshop following completion of the first TS GWAS. The
GGRI collaborative resulted in both the targeted replication study
described above (Paschou et al., 2014) and acted as another
major contributing source for the second international TS GWAS
and CNV studies. Similarly, TIC Genetics has contributed data
from over 400 TS parent-proband trios to the latest TS GWAS.
TSAICG and TIC Genetics are also currently collaborating in
a joint analysis of exome sequencing data aimed at identifying
recurrent, de novo mutations in TS parent-proband trio families
(see below). Most recently, all of the above collaborative groups
have also contributed their GWAS data to the Psychiatric
Genomics Consortium (PGC) and formed the TS component of
the TS and OCDWorking Group of the PGC.
THE TOURETTE INTERNATIONAL
COLLABORATIVE GENETICS (TIC
GENETICS) STUDY—WHOLE EXOME
SEQUENCING IN FAMILIES WITH TS
The TIC Genetics Study is a large, multi-center effort established
in 2011 (http://tic-genetics.org) with several goals, including
(1) to create a large, central repository for sharing clinical
data and biomaterials from genotypically and phenotypically
well-characterized affected individuals and their relatives; (2)
to increase our understanding of the genetic architecture of
tic disorders through identification of risk genes and loci,
and enumeration of the number of these genes and loci that
contribute risk; and (3) to leverage these findings alongside
systems biological approaches to provide insights into the
neurobiology underlying these disorders (Dietrich et al., 2014).
Patients are recruited at more than 20 sites from USA,
Europe, and South Korea, including academic research and
mental health care centers (Dietrich et al., 2014). Recruiting
focusses on both multiplex families and apparently-simplex
trios. Following extensive phenotyping, blood is drawn and
processed at the NIMH Center for Collaborative Genomics
Research onMental Disorders at RUCDR (http://www.rucdr.org)
for DNA and RNA extraction, lymphocytes cryopreservation,
and lymphoblastoid cell lines establishment. Anonymized clinical
data and biomaterials are stored in a sharing repository
located within the National Institute for Mental Health Center
for Collaborative Genomics Research on Mental Disorders
(www.nimhgenetics.org). Importantly, this study has been
designed to optimize compatibility with other TS genetic
consortia and researchers, as this will be critical to advancing our
understanding of this disorder (Dietrich et al., 2014).
The TIC Genetics study leverages multiple genomewide
approaches for identifying rare, large effect size variants, focusing
both on identifying highly penetrant genetic variants segregating
in multiply affected pedigrees and on de novo mutations
identified in simplex families. Genomewide methods include
genotyping microarrays for linkage analysis (Ercan-Sencicek
et al., 2010) and CNV detection (Fernandez et al., 2012), and
whole-exome sequencing (WES) for SNP and insertion-deletion
variant (indel) detection. Efforts of TIC Genetics investigators led
to the implication of histaminergic pathway genes in TS etiology
(Ercan-Sencicek et al., 2010; Fernandez et al., 2012).
TIC Genetics is currently finishing analysis of WES data from
325 simplex TS trios. The main focus is the detection of de novo
SNPs and indels, largely due to the success of this gene discovery
Frontiers in Neuroscience | www.frontiersin.org 5 August 2016 | Volume 10 | Article 351
Georgitsi et al. Large-Scale Collaborations for TS Genetics
approach in ASD (Sanders et al., 2015). Because of the rarity of
de novomutations and their large effect size, recurrent mutations
can be leveraged to identify risk genes with high confidence.
Excitingly, the identification of risk genes, in a hypothesis-
free manner, facilitates systems biological analyses aimed at
answering critical questions about the underlying neurobiology
of TS. Systems approaches alongside gene-expression data from
the developing human brain may have already been quite fruitful
in this regard (Willsey et al., 2013).
EMTICS: EUROPEAN MULTICENTRE TICS
IN CHILDREN STUDY; EXPLORING
GENE-ENVIRONMENT INTERACTIONS
THAT UNDERLIE TS ETIOLOGY
EMTICS is a multi-national study funded by the European
Commission under the Seventh Framework Programme,
including 17 clinical sites from across Europe (http://emtics.eu).
It is prospectively designed to offer, for the first time, the
opportunity to evaluate environmental risk factors that may
lead to tic exacerbation but also, new tic onset, while correlating
to genomic background. Two unique patient cohorts form
the core of EMTICS: The ONSET study involves follow-up of
375 high-risk children aged 3–10 years who have a first degree
relative with a diagnosis of TS and at study entry have no tics.
The COURSE study includes and follows for up to 3 years, 700
children, and adolescents aged 3–16 years with a known chronic
tic disorder or TS.
Individual genetic background alone cannot predict the
risk for TS and a role of exposure to psychosocial stress,
pre- and perinatal difficulties, and GAS infections (Hoekstra
et al., 2013; Mathews et al., 2014) in TS etiology has been
shown. The human pathogen GAS is a major cause of
common pharyngitis, but also of significant post-streptococcal
autoimmune multi-organ sequelae associated with the existence
of host autoantibodies against GAS antigens, including rheumatic
fever and Sydenham’s chorea (Church et al., 2002). In the
1990s, Swedo et al. (1998) described a clinical phenotype, named
Paediatric Autoimmune Neuropsychiatric Disorders Associated
with Streptococcal Infections (PANDAS). Although it is still
controversial whether PANDAS criteria can be used to designate
a unique clinical entity, further research into the potential role of
the innate and adaptive immune systems in the pathogenesis of
tics and OCD is warranted (Martino et al., 2009; Murphy et al.,
2010). The etiological link between GAS infections and TS/OCD
may be related to an autoimmune process, following the model
of molecular mimicry, according to which structural similarity
between streptococcal and cerebral antigens might elicit a
pathogenic cross-reactivity of antibodies originally targeting GAS
antigens to host antigens.
Within EMTICS, the main hypothesis is that the onset of
TS is dependent on identifiable genetic factors interacting with
identifiable environmental factors. The study aims to test the
likelihood that the development of new tics or tic exacerbation
in individuals with a specific genetic background, is increased
by recent exposure to pharyngeal GAS carriage or infection. The
study investigates the genomic background of studied individuals
through genomewide genotyping, in relation to new tic onset and
tic exacerbation, correlating to the presence of GAS in throat
swabs, comorbidities, pre- and perinatal difficulties, psychosocial
stress (also measured via cortisol levels in hair follicles), and
immunological measures. Transcriptome-wide gene-expression
profiles of patients at points of tic exacerbation and tic remission
as well as before and after tic onset in newly-diagnosed patients
will also reveal, for the first time, pathways that are activated
during the course or onset of TS. The first patient was enrolled
in March 2013 and the study will conclude in 2017. The potential
observation of a pathogenic link between an environmental
immune-activating factor and risk for the development of a tic
disorder and/or OCD may pave the way to the application of
immune-modulating prophylactic and treatment approaches in
these conditions.
TS-EUROTRAIN—COORDINATING
LARGE-SCALE STUDIES AND TRAINING
THE NEXT GENERATION OF EXPERTS
FOR TS
In an effort to address the need for large-scale collaboration
in order to tackle the multi-faceted etiology of TS but also
train the next generation of young experts in the field, the
Marie Curie Initial Training Network TS-EUROTRAIN was
established, supported by the European Commission (http://
ts-eurotrain.eu). Collaborative efforts of 14 academic institutes
along with 12 PhD students form a highly multidisciplinary and
inter-sectorial team, with the European experts in the study of
TS collaborating with leading scientists in the USA. Building
bridges between academia and industry is key to the network
with two industrial partners providing pioneering expertise to
the network: deCODE Genetics, a large genetic services and
research provider and Boehringer Ingelheim PHARMA, one of
the 20 largest pharmaceutical companies in the world. Twelve
individual, yet complementary, projects interact to form a
comprehensive study of TS and comorbidities from genetics and
epigenetics through to physiology, brain anatomy, and function.
These projects can roughly be divided into three groups by their
main approach; genetic (and epigenetic), animal models, and
human neuroimaging, respectively.
TS-EUROTRAIN aspires to act as an interface bringing
together multiple large-scale efforts in the field. The main
scientific goals are to assemble and interrogate a large genetic
database for the evaluation of the genetic architecture of TS, to
explore the role of gene-environment interactions in TS etiology
including, for the first time, the effects of epigenetic phenomena,
and to gain new insights into the neurobiological mechanisms
of TS via cross-sectional and longitudinal neuroimaging studies
and animal studies. Among the main expected outcomes of
TS-EUROTRAIN will be the largest meta-analysis of European
patient cohorts, resulting in a total of about 3000 patients
with TS analysed for about 700,000 genetic markers across
the genome as well as genomewide CNV studies in European
patient cohorts. Furthermore, already, TS-EUROTRAIN has
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produced the first ever epigenome-wide association study
for tics, analysing data from the Netherlands Twin Register
(Zilhão et al., 2015). This study interrogated 411,469 autosomal
methylation sites in 1678 individuals. Although no site reached
genomewide significance, the top hits include several genes
and regions previously associated with neurological disorders
and warrant further investigation (Zilhão et al., 2015). Systems
biology approaches and integration of data from multiple
sources are main aspects of TS-EUROTRAIN methodology.
Thus, large-scale data analysis and novel algorithm development
for integration of data from “omics” platforms but also
clinical and neuroimaging data are important parts of the
study.
The academic and industrial partners form a unified training
infrastructure to provide interdisciplinary training for TS.
Specialized training covers cutting-edge scientific areas ranging
from basic neuroscience and genomics to bioinformatics and
computer science. Direct interaction of the network with
European patient groups (Tourette-Gesellschaft Deutschland
e.V., Germany and Netherlands Foundation of patients with
TS, Netherlands) provides a unique opportunity to learn from
patients and disseminate scientific knowledge of TS to large
non-scientific audiences. Undertaking a comprehensive scientific
and outreach programme, TS-EUROTRAIN aims to build
Pan-European infrastructure and render TS into an example
disorder for the study of other neurodevelopmental disorders
and the development of European policies for the promotion of
childhood mental health.
CONCLUSIONS
Collaborative efforts of dedicated researchers from around
the world have brought us on the verge of a new era,
promising exciting, and rapid discoveries in the field of TS
genetics. Multiple resources are coming together for TS genetic
research; large well-characterized patient cohorts, specialized
epidemiological databases, novel genomics technologies, and
sophisticatedmethodology for the analysis of large-scale datasets.
Systems biology approaches and integration of data from
multiple sources and “omics” platforms can be expected to reveal
novel facets of TS etiology, while cross-disorder meta-analysis for
the identification of overlapping risk factors is shifting our view
toward a whole spectrum of neurodevelopmental phenotypes.
Importantly, the individual large-scale efforts described here, are
ultimately joining their powers with the goal to boost power
and identify definitive susceptibility genes for TS. These scientific
alliances in concert with parallel large scale efforts in psychiatric
genetics such as the PGC hold the promise to get us over the
“precipice” and enter a new phase in TS gene discovery that
may lead us to new pathophysiologic mechanisms underlying the
disorder.
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